Journal
CLINICA CHIMICA ACTA
Volume 411, Issue 23-24, Pages 1935-1939Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.cca.2010.08.009
Keywords
Prostate specific antigen (PSA); Glycosylation; Enzyme-linked immunosorbent assay (ELISA); Enzyme-linked lectin assay (ELLA); Lectin; Fucosylation; Biomarker
Categories
Funding
- Against Breast Cancer [1121258]
Ask authors/readers for more resources
Background: Prostate specific antigen (PSA) measurement is used for the diagnosis of prostate cancer (PCa) but the test lacks specificity due to the number of false positive readings. The glycosylation of PSA is altered in PCa but studies in this area have been limited to few clinical samples and/or require advanced laboratory facilities. An assay to assess PSA glycosylation was established using equipment available in most routine biomedical testing laboratories. Methods: Serum samples from patients with PCa or benign prostatic hyperplasia (BPH) were used. PSA (range 4-10 ng/ml) was affinity purified, separated and probed with the lectin Ulex europaeus (UEA-1; specific for alpha 1,2 linked fucose). An enzyme-linked immunosorbent lectin assay (ELLA) with colorimetric detection was devised and PSA fucosylation assessed in a further independent set of 26 samples. Results: Free PSA (fPSA) from PCa patients showed a significant increase in fucosylation compared with fPSA from patients with BPH. The ELLA was 92% specific and 69% sensitive for PCa over BPH. In comparison, fPSA measurement was 70% specific and 56% sensitive (threshold set to 25% tPSA) for PCa over BPH. Conclusions: Changes in glycosylation of PSA were identified using 50 mu l of serum with PSA in the range of 410 ng/ml, this represents a more specific and sensitive test for PCa based on fucosylation changes of fPSA. (C) 2010 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available